Evaluating Clinically Validated NMT Inhibitors as ADC Payloads
- Characterizing the mechanism of action of NMT inhibitors across tumor models, to understand their potential as highly potent ADC payloads
- Assessing the preliminary clinical safety and antitumor efficacy of Zelenirstat as an oral therapeutic, to establish its therapeutic window and translational potential for payload development
- Evaluating the initial performance of NMT inhibitors as ADC payloads, to determine their effects on targeted cytotoxicity, payload stability, and antitumor activity while minimizing off-target toxicities